These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 19382004)

  • 1. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
    Denzinger S; Burger M; Fritsche HM; Bertz S; Hofstädter F; Wieland WF; Hartmann A; Otto W
    Scand J Urol Nephrol; 2009; 43(4):282-7. PubMed ID: 19382004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
    Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
    Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
    Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
    Urol Oncol; 2010; 28(3):285-9. PubMed ID: 18976938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease?
    Shindo T; Masumori N; Fukuta F; Miyamoto S; Tsukamoto T
    Jpn J Clin Oncol; 2010 Feb; 40(2):153-6. PubMed ID: 19841100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.
    Smaldone MC; Jacobs BL; Smaldone AM; Hrebinko RL
    Urology; 2008 Sep; 72(3):613-6. PubMed ID: 18554696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
    Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
    BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
    Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?
    Denzinger S; Fritsche HM; Otto W; Blana A; Wieland WF; Burger M
    Eur Urol; 2008 Jan; 53(1):146-52. PubMed ID: 17624657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.